DMF is a drug used to treat relapsing forms of multiple sclerosis and psoriasis, and is being tested in clinical trials for the treatment of several types of cancer, since it is linked with a wide range of pathways and kinases involved in tumor progression, such as the KEAP1–Nrf2, NF-κB, ERK, and MAPK pathways [119]. Here, KEAP1 is linked to cancer.